SlideShare uma empresa Scribd logo
1 de 35
Baixar para ler offline
Spinal muscular atrophy (sma)
DEFINITION
• Neuromuscular disorders that present in the
newborn period with hypotonia and weakness
can be caused by a variety of conditions that
affect the central nervous system (brain or spinal
cord), peripheral nervous system, or skeletal
muscle.
• Spinal muscular atrophy (SMA) is characterized by
degeneration of the anterior horn cells in the
spinal cord and motor nuclei in the lower
brainstem, which results in progressive muscle
weakness and atrophy.
GENETICS
• The inheritance pattern of chromosome 5q-
related SMA is autosomal recessive.
• The most common mutation of SMN1 is a
deletion of exon 7.
• The differences in SMN protein activity and
phenotypic expression appear to be related in
part to a modifying gene, called survival
motor neuron (SMN).
Spinal muscular atrophy (sma)
EPIDEMIOLOGY
• The incidence of spinal muscular atrophy
ranges from 4 to 10 per 100,000 live births,
• the carrier frequency of disease-causing SMN1
mutations ranges from 1:47 to 1:90.
• SMA is the most common monogenic cause of
infant mortality.
Carrier rate
• Approximately 1 in 54 people are carriers1
Birth rate
1. Kolb SJ & Kissel JT. Neurol Clin 2015;33:831–846; 2. About SMA: Overview. Available at: http://smafoundation.org/about-sma/, accessed March 2021
3. Verhaart I et al. J Neurol 2017;264:1465–1473; 4. Farrar MA et al. Ann Neurol 2017;81:355–368; 5. Verhaart I et al. Orphan J Rare Dis 2017;12:124.
SMA is a rare disease
Worldwide
~1 in 11,000 live births1,4
USA
~1 in 6000–10,000 live
births2
Europe
~1 in 3900–16,000 live
births3
There may be variation in the birth
rate between countries because
there is a difference in the
incidence of SMA between
ethnicities5
Classification
• These diseases are classified as types 0 through
4, depending upon the age of onset and clinical
course.
• SMA type 0 (prenatal onset) and SMA type 1
(infantile onset) are the most common and
severe types.
• SMA type 2 and SMA type 3 have a later onset
and a less severe course.
• SMA type 4 (adult onset) is the least severe type.
CLINICAL FEATURES
• The diagnosis of SMA should be suspected for any infant with
unexplained weakness or hypotonia.
• Weakness is usually symmetrical and more proximal than distal;
generally, it is greater in the legs than in the arms
• Additional clues suggesting the diagnosis in infants, children, or
adults include a history of motor difficulties, Impaired head
control, Weak cry and cough, progressive respiratory
insufficiency, Swallowing and feeding difficulty, sleep
disturbances, hyporeflexia or areflexia, tongue fasciculations,
and signs of lower motor neuron disease on examination.
• Sensitivity & and intellect are not affected.
Clinical classification of SMA
• Onset: 10–30 years
• Walk independently
– Ability may be
affected later in
life
• Normal life
expectancy
Type 0 Type 1 Type 2 Type 3 Type 4
• Onset: Prenatal
• Short life
expectancy
(usually <1
month)
• Onset: 0–6
months
• Never sit1
• Short life
expectancy (<2
years)
• Onset: <18 months
• Sit independently
• Never walk
• Survival into
adulthood (prognosis
dependent on
respiratory
involvement)
• Onset: >18 months
• Walk independently1
– Need assistance
– Lose the ability
over time
• Normal life
expectancy
Early onset Late onset
Spinal muscular atrophy (sma)
DIAGNOSIS
• Clinical : The diagnosis of SMA should be suspected for any
infant with unexplained weakness or hypotonia .
• Molecular genetic testing with targeted mutation analysis
can confirm the diagnosis of SMA by detection of
homozygous deletions of exons 7 of SMN1.
• Electromyography in SMA shows abnormal spontaneous
activity with fibrillations and positive sharp waves.
• Muscle biopsy reveals large groups of circular atrophic type
1 and 2 muscle fibers interspersed among fascicles of
hypertrophied type 1 fibers.
• SMA was added to the Recommended Uniform Screening
Panel (RUSP) for newborns in the United States in 2018,
and several states have begun newborn screening for SMA.
Early diagnosis of SMA is essential for best
patient outcomes
• Timely diagnosis is important in all types of SMA, as the success of treatments or medical interventions may
depend on identifying individuals as early as possible to begin treatment before irreversible
neuronal loss1
– For example, in infants with Type 1 SMA, loss of motor neurons occurs rapidly, within months of life1
– Type 1 SMA accounts for about 50% of individuals diagnosed with SMA
0–3 months
Rapid loss of
motor units
0–6 months
Severe denervation
>95% motor unit loss
Type 1 SMA2
Early diagnosis of SMA is critical
Management
• Conservative treatment.
• Pharmacological treatment
Occupational
therapist
Orthopaedic
consultant
Physiotherapist
Physician
Psychologist
Acute care
clinicians
Consultant
neurologist
Gastroenterologist
Neuromuscular
care specialist
Nutritionist
Pulmonologist
Speech-language
pathologist
The MDT can
consist of:
Conservative treatment
• A multidisciplinary approach is key for the management of individuals
with SMA
• In SMA, it is important to monitor the various aspects that are known to
be involved in disease progression and, when possible, provide
anticipatory care.
• Nusinersen
• Onasemnogene abeparvovec.
• Risdiplam.
Pharmacological treatment
• Since the 2000s, various therapeutics have been developed that aim to restore the physiological levels of SMN proteins.
This can be achieved in different ways:
FUNCTIONAL SMN PROTEIN LEVELS CAN BE RESTORED IN DIFFERENT WAYS
SMN, survival motor neuron.
1. Rao VK et al. J Manag Care Spec Pharm 2018;24:S3–S16; 2. Poirier A et al. Pharmacol Res Perspect 2018;6:e00447.
3.Butchbach MER. Front Mol Biosci 2016;3:7; 4. D'Amico A et al. Orphanet J Rare Dis 2011;6:71.
Gene therapy can beused to delivera functionalcopy ofhuman SMNgene to the patient’s
own cellstoreplace the missingor defective SMN1gene1
SMN2 expression from SMN2gene transcriptscan be increasedif the inclusionofexon 7is
promoted, thereby producing full-length,functional SMN2 protein2
Graphics createdwithBioRENDERsoftware
Viruscontaining
thecorrectSMN copy
SMN1 gene replacement therapy SMN2 gene transcript manipulation 2-
4
Drugs used for SMA
Nusinersen
Administered via lumbar puncture
Does not cross the blood–brain
barrier
The estimated cost of lifetime
nusinersen treatment is USD 6.3
million (2019)
Trained medical staff and hospital
facilities
are required for administration
Onasemnogene abeparvovec-xioi
Limited indication in the US and
Japan
for use in infants aged <2 years only
The initial cost of treatment is
USD 2.1 million for a single dose
IV administration is unsuitable for
older, heavier patients
Co-medication with steroids may be
required for up to ⁓3 months
Limited indication in Europe for use
in individuals with Type 1 SMA, or
affected individuals with ≤3 copies of
the SMN2 gene
3’ss, 3’ splicing site; 5’ss, 5’ splice site; ESE, exonic splicing enhancer; snRNP, small nuclear RNA; SMA, spinal muscular
atrophy; SMN, survival of motor neuron.
Sivaramakrishnan M, et al. Nat Commun. 2017; 8:1476.
MECHANISM OF ACTION
• Risdiplam binds two sites in SMN2 pre-mRNA
– 5'ss of intron 7
– ESE2 in exon 7
• Binding to the 5’ ss of intron 7 improves
recognition by U1 snRNP
• U1 snRNP promotes inclusion of exon 7
• The unique specificity of binding two sites
increases levels of full-length SMN mRNA
and protein while reducing the impact on
splicing of other pre-mRNA
Maturefull-lengthSMN2mRNA
SMN2Pre-mRNA
Exon6 Exon8
Exon7
Intron6 Intron7
5’ss
ESE2
3’ss 5’ss 3’ss
Spliceosome recruitedto
initiatethesplicingprocess
ISS-N1
Exon6 Exon8
Exon7
Exon7is retainedandamature
full-lengthSMN2mRNAis generated
Bindingto 5’ssandimprovement
of
U1/5’ssinteraction
risdiplam
risdiplam
Bindingtothe exonic splicing
enhancer to promote
Exon 7 inclusion
Risdiplam
Risdiplam is being investigated
The FISH clinical program has enrolled individuals with SMA across a broad spectrum of
disease severity (Type 1–3), from newborns to 60-year-old adults, from pre-symptomatic
to very weak individuals, both treatment-naïve and previously treated, accounting for
the varied needs of the SMA population1–4
*Target enrolment, currently recruiting; †Actual subject number enrolled.
1. ClinicalTrials.gov NCT03779334, accessed March 2021; 2. ClinicalTrials.gov NCT02913482, accessed May 2020; 3.
ClinicalTrials.gov NCT02908685, accessed May 2020; 4. ClinicalTrials.gov NCT03032172, accessed March 2021; 5. Baranello G et al.
2019. Presented at the Cure SMA Annual Conference 2019, California, USA. Motor function; 6. Mercuri E et al. Presented at the
Cure SMA Annual Conference, 28 June–1 July 2019, Anaheim, CA, USA.
FIREFISH2
• Type 1 SMA
• 1–7 months old
• Dose finding (N=21)5
• Efficacy and safety
(N=41†)5
SUNFISH3
• Type 2 or 3 SMA
• 2–25 years old
• Dose finding (N=51)6
• Efficacy and safety
(N=180†)6
JEWELFISH4
• Type 1, 2 or 3 SMA
• 6 months–60 years old
• Previous SMA treatment
• PK/PD and safety (N=174†)
RAINBOWFISH1
• Pre-symptomatic SMA
• Birth–6 weeks old
• Efficacy and safety
(N=25*)
6 months 5 years 10
years
20
years
60 years
Age at enrolment
Birth
RAINBOWFISH
FIREFISH SUNFISH
JEWELFISH
FIREFISH is a two-part study that enrolled infants
aged 1–7 months with Type 1 SMA1
*A comprehensive list of the primary and secondary endpoints can be found at: https://clinicaltrials.gov/ct2/show/NCT02913482.
BSID-III, Bayley Scales of Infant and Toddler Development, Third Edition; CHOP-INTEND, Children’s Hospital of Philadelphia Infant Test
of Neuromuscular Disorders;
HINE-2, Hammersmith Infant Neurological Examination, Section 2; PD, pharmacodynamics; PK, pharmacokinetics.
1. ClinicalTrials.gov NCT02913482, accessed March 2021; 2. Servais L et al. Presented at a virtual meeting. 28 April 2020.
FIREFISH
Type 1 SMA
1–7 months old
Rationale1 Assess the safety and efficacy of risdiplam in infants with Type 1 SMA
aged 1–7 months
Primary
endpoints*1
Part 1
Determine the dose for
the confirmatory Part 2
Part 2
Proportion of infants who are sitting without support
at Month 12 (as assessed by item 22 of the BSID-III
Gross Motor Scale)
Key secondary
endpoints*
• Assess the safety,
tolerability and
PK/PD
of risdiplam1
• Evaluate motor function using the BSID-III, the
CHOP-INTEND and the HINE-2 at 12 months1
• Assess the time to death or permanent
ventilation1
• Evaluate the ability to swallow and feed orally at
Month 121,2
• Assess the safety, tolerability and PK/PD of
risdiplam1
Infants enrolled in FIREFISH with Type 1 SMA
from 15 countries1
1. ClinicalTrials.gov NCT02913482, accessed March 2021; 2. Bladen CL et al. J Neurol 2014;261:152–163.
• Belgium
• Brazil
• China
• Croatia
• France
• Italy
• Japan
• Poland
• Russia
• Saudi Arabia
• Serbia
• Spain
• Switzerland
• Turkey
• USA
Standards of care may vary between countries and may have an impact on patient outcomes2
FIREFISH Part 1 (Cohort B)*:Conclusions at 24 Month1
*High-dose cohort. † Event free in FIREFISH is defined as alive with no permanent ventilation (i.e. no tracheostomy or BiPAP ≥16 hours per day continuously for >3 weeks or continuous intubation >3 weeks, in the absence of, or
following the resolution of, an acute reversible event). ‡ As measured by HINE-2. § As measured by CHOP- INTEND. ǁ Safety statements are based on data from all infants in Cohort A and B. Data cut-off: 03 March 2020.
BSID-III, Bayley Scales of Infant and Toddler Development, Third Edition; CHOP-INTEND, Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders; HINE-2, Hammersmith Infant Neurological Examination,
Module 2; SMA, spinal muscular atrophy.
1. Baranello G et al. FIREFISH Part 1: 24-month safety and exploratory outcomes of risdiplam (RG7916) in infants with Type 1 spinal muscular atrophy (SMA). Presented at the 25th International Annual Congress of the World
Muscle Society, 28th Semptember-2nd October 2020
Infants continued to
achieve motor
milestones, such as
sitting and standing with
support† which would never be
seen in natural history studies
*Event free in FIREFISH is defined as alive with no permanent ventilation (i.e. no tracheostomy or BiPAP ≥16 hours per day continuously for >3 weeks or continuous intubation >3 weeks, in the absence of, or following the resolution of, an acute reversible event).†As
measured by HINE-2.
‡Hospitalizations include hospital admissions ≥1 night. BiPAP, Bilevel Positive Airway Pressure; BSID-III, Bayley Scales of Infant and Toddler Development, third edition;
1. Darras BT, Masson R, Mazurkiewicz-Bełdzińska M, et al. FIREFISH Part 2: 24-month efficacy and safety of risdiplam in infants with Type 1 spinal muscular atrophy (SMA). Presentation at: American Academy of Neurology Annual Meeting; April 17-April 22, 2021; Virtual.
83%
(34/41)
of infants were event
free* at Month 24
of infants were alive and
93%
(38/41)
61%
(25/41)
All patients treated
with Risdiplam who
were able to sit without support
for 5 seconds at Month 12
maintained this ability at Month 24
of infants were
sitting without support for at least
5 seconds at Month 24, as
measured by the BSID-III
No drug-related safety findings led to withdrawal in FIREFISH Part 2
34%
(14/41)
of all infants did not
require hospitalization‡
during 24 months of
treatment
of infants alive were
able to swallow after
24 months of treatment
95%
(36/38)
FIREFISH Part 2: 24-months Data
SUNFISH is a two-part study which enrolled
individuals with Type 2/3 SMA, aged 2–25 years
SUNFISH
Type 2/3 SMA
2–25 years old
Rationale
Evaluate the safety and efficacy of risdiplam in individuals with Type 2/3 SMA
aged 2–25 years, which is representative of the diverse real-world patient population
Primary
endpoints*
Part 1
Determine the dose for
the confirmatory Part 2
Part 2
Evaluate motor function using the MFM-32 at 12 months
Key secondary
endpoints*
Assess the safety,
tolerability and PK/PD
of risdiplam
• Evaluate the proportion of participants achieving
stabilization or improvement in motor function as
assessed by the MFM at Month 12
• Evaluate motor function using the RULM and the
HFMSE at 12 months
• Assess independence using the SMAIS at 12 months
• Assess the safety, tolerability and PK/PD of risdiplam
*A comprehensive list of primary and secondary endpoints can be found at:
https://clinicaltrials.gov/ct2/show/ NCT02908685.
MFM, Motor Function Measure; PD, pharmacodynamics; PK, pharmacokinetics; RULM, Revised Upper Limb
Module.
ClinicalTrials.gov NCT02908685, accessed March 2021
Key exclusion criteria1
SUNFISH was designed to include a patient population
representative of the diversity of real-world individuals
living with Type 2/3 SMA1–3
A comprehensive list of inclusion/exclusion criteria can be found at: https://clinicaltrials.gov/ct2/show/study/NCT02908685.
SMN, survival of motor neuron.
1. ClinicalTrials.gov NCT02908685, accessed March 2021; 2. Mercuri E et al. Presented at the Cure SMA Annual Conference, 28 June–
1 July 2019, Anaheim, CA, USA;
3. Mercuri E et al. Presented at SMA Europe, 5–7 February 2020, Évry, France.
Key inclusion criteria1
Part 1 Part 2
• Previous participation in an SMN2-targeting
study or gene therapy study
• Planned (within 18 months) or previous
(<1 year prior) surgery for scoliosis or hip
fixation
Part 1 Part 2
• Confirmed genetic diagnosis of 5q-autosomal
recessive SMA
• Aged 2–25 years with Type 2/3 SMA
Type 2, or ambulatory
or non-ambulatory
Type 3 SMA
Type 2 or
non-ambulatory
Type 3 SMA
SUNFISH enrolled individuals with a broad functional and clinical range
including those with severe scoliosis or contractures2,3
SUNFISH enrolled individuals with Type 2/3 SMA
from 15 countries1
• Belgium
• Brazil
• Canada
• China
• Croatia
• France
• Germany
• Italy
• Japan
• Poland
• Russia
• Serbia
• Spain
• Turkey
• USA
Standards of care may vary between countries and may have an impact on patient outcomes2
1. ClinicalTrials.gov NCT02908685, accessed March 2021; 2. Bladen CL et al. J Neurol 2014;261(1):152–163.
Summary: SUNFISH Part 11
SUNFISH Part 1 is ongoing globally2
98% of individuals in
SUNFISH Part 1 have been
treated for at least 12
months.
1 dropout in the first 12 months
(not because of any safety reason.)
SUNFISH Part 1 helped to
determine the dose for Part
2 of the study (primary
endpoint for Part 1)
100% survival
No deaths or
drug-related safety
findings leading to
treatment
withdrawal
Exploratory MFM-32 results
indicate treatment with risdiplam
led to improvement in motor
function compared with
NatHis-SMA
A clinically meaningful increase
in the MFM-32 total score was
observed in individuals
independent of age or
functional status at baseline
Data cut-off for SUNFISH Part 1: 09 January 2019.
MFM, Motor Function Measure.
1. Mercuri E et al. Presented at the Cure SMA Annual Conference, 28 June–1 July 2019, Anaheim, CA, USA; 2.
ClinicalTrials.gov NCT02908685, accessed March 2021.
Individuals receiving risdiplam gain or maintain motor function
Risdiplam is the first SMA treatment to have positive pivotal placebo-controlled data
in a broad population of children, adolescents and adults—preserving and potentially
enabling motor function independence for individuals with Type 2 SMA
and non-ambulant Type 3 SMA
MFM-32 and RULM scores
showed that risdiplam
significantly improved
motor function after
12 months
versus placebo
No treatment-related safety
findings have led to
treatment withdrawal in
SUNFISH Part 2
Risdiplam improved
independence in activities
of daily living, as assessed using
the novel SMAIS measure
MFM, Motor Function Measure; RULM, Revised Upper Limb Module; SMAIS, SMA Independence Scale.
Mercuri E et al. Presented at SMA Europe, 5–7 February 2020, Évry, France.
Summary: SUNFISH Part 2
RAINBOWFISH is recruiting presymptomatic infants
with genetically diagnosed SMA (birth–6 weeks)
RAINBOWFISH1
Presymptomatic
Birth–6 weeks old
Rationale1 Assess the safety, efficacy, PK and PD of risdiplam in pre-symptomatic infants with
genetically diagnosed SMA (birth–6 weeks old)
Primary
endpoint*1
Proportion of participants with two copies of the SMN2 gene and a baseline CMAP†
≥1.5 mV who are sitting‡ without support at Month 12
Key secondary
endpoints*1
• Proportion of participants
developing clinically manifested
SMA
• Time to permanent ventilation
and/or death
• The achievement of motor
milestones defined in the BSID-III
and by
the HINE-2
• Change from baseline score in
the CHOP INTEND
• Growth measures
• Ability to swallow and amount of
solid food intake
• Degree of innervation by CMAP
• PK effects
• Respiratory effects by
plethysmography
*A comprehensive list of primary and secondary endpoints can be found at: https://clinicaltrials.gov/ct2/show/NCT03779334; †CMAP is the composite electrical
activity within the target muscle resulting from synchronous activation of a group of motor neurons within a nerve bundle.3 A low CMAP score indicates severe
denervation and high disease severity;4 ‡Sitting is defined as ‘sits without support for 5 seconds’, as assessed by Item 22 of the BSID-III Gross Motor Scale.
BSID-III, Bayley Scales of Infant and Toddler Development, Third Edition; CHOP INTEND, Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders;
CMAP, compound muscle action potential; HINE-2, Hammersmith Infant Neurological Examination, Section 2; PD, pharmacodynamics; PK, pharmacokinetics; SMN,
survival of motor neuron.
1. ClinicalTrials.gov NCT03779334, accessed March 2021; 2. Kolb SJ et al. Ann Clin Trans Neurol 2016;3(2):132–145; 3. . Treat NMD https://treat-nmd.org/wp-
content/uploads/2016/08/sma-SMA_M.2.2.002.pdf (accessed March 2021); ; 4. Lewelt AJ et al. Muscle Nerve 2010;42(5):703–708.
RAINBOWFISH is recruiting presymptomatic infants
with genetically diagnosed SMA (birth–6 weeks)1
RAINBOWFISH1
Presymptomatic
Birth–6 weeks old
Rationale1 Assess the safety, efficacy, PK and PD of risdiplam in presymptomatic infants with
genetically diagnosed SMA (birth–6 weeks old)
Primary
endpoint*1
Proportion of participants with two copies of the SMN2 gene and a baseline CMAP†
≥1.5 mV who are sitting‡ without support at Month 12
Key secondary
endpoints*1
• Proportion of participants
developing clinically manifested
SMA
• Time to permanent ventilation
and/or death
• The achievement of motor
milestones defined in the BSID-III
and by
the HINE-2
• Change from baseline score in
the CHOP INTEND
• Growth measures
• Ability to swallow and amount of
solid food intake
• Degree of innervation by CMAP
• PK effects
• Respiratory effects by
plethysmography
*A comprehensive list of primary and secondary endpoints can be found at: https://clinicaltrials.gov/ct2/show/NCT03779334; †CMAP is the
composite electrical activity within the target muscle resulting from synchronous activation of a group of motor neurons within a nerve bundle.3 A
low CMAP score indicates severe denervation and high disease severity;4 ‡Sitting is defined as ‘sits without support for 5 seconds’, as assessed by
Item 22 of the BSID-III Gross Motor Scale.
BSID-III, Bayley Scales of Infant and Toddler Development, Third Edition; CHOP INTEND, Children's Hospital of Philadelphia Infant Test of
Neuromuscular Disorders; CMAP, compound muscle action potential; HINE-2, Hammersmith Infant Neurological Examination, Section 2; PD,
pharmacodynamics; PK, pharmacokinetics; SMN, survival of motor neuron.
1. ClinicalTrials.gov NCT03779334, accessed March 2021; 2. Kolb SJ et al. Ann Clin Trans Neurol 2016;3(2):132–145; 3. Treat NMD https://treat-
nmd.org/wp-content/uploads/2016/08/sma-SMA_M.2.2.002.pdf (accessed March 2021); 4. Lewelt AJ et al. Muscle Nerve 2010;42(5):703–708.
• In 2016, a Natural History study was performed which assessed motor function and putative
electrophysiological, protein and molecular biomarkers in both affected and unaffected infants
aged <6 months2
• This study was useful when designing RAINBOWFISH as it provided several reference values
(particularly the cut-off baseline CMAP† value of ≥ 1.5 mV for the primary endpoint)2
1. Risdiplam USPI
1. Risdiplam USPI
Risdiplam Dosage
60 mg/80 ml
0.75mg/ml
Shelf-life: 64 days
after reconstitution;
2years for powder
2 Months 2 Years ≈7 Years/20kg Adult
0.2mg/kg/day 0.25mg/kg/day 5mg/da
y
1 bottle/≈60
days
1 bottle/≈20
days
1 bottle/max*
12 days
Risdiplam USPI
M-LB-00000264
Risdiplam is not yet registered in Iraq
THANKS FOR YOUR ATTENTION

Mais conteúdo relacionado

Mais procurados

Mais procurados (20)

Adem
AdemAdem
Adem
 
Amyotrophic lateral sclerosis (als)
Amyotrophic lateral sclerosis (als)Amyotrophic lateral sclerosis (als)
Amyotrophic lateral sclerosis (als)
 
Syringomyelia
SyringomyeliaSyringomyelia
Syringomyelia
 
Spinal muscle atrophy SMA: make it easy
Spinal muscle atrophy SMA: make it easySpinal muscle atrophy SMA: make it easy
Spinal muscle atrophy SMA: make it easy
 
Friedreich’s Ataxia
Friedreich’s Ataxia Friedreich’s Ataxia
Friedreich’s Ataxia
 
Congenital myopathy
Congenital myopathyCongenital myopathy
Congenital myopathy
 
Hereditary spastic paraplegia
Hereditary spastic paraplegiaHereditary spastic paraplegia
Hereditary spastic paraplegia
 
Guillain - Barré syndrome
Guillain -  Barré syndrome  Guillain -  Barré syndrome
Guillain - Barré syndrome
 
Hereditary motor and sensory neuropathy
Hereditary motor and sensory neuropathyHereditary motor and sensory neuropathy
Hereditary motor and sensory neuropathy
 
Cerebellum & ataxia
Cerebellum & ataxiaCerebellum & ataxia
Cerebellum & ataxia
 
Muscular dystrophies
Muscular dystrophiesMuscular dystrophies
Muscular dystrophies
 
Myopathies
MyopathiesMyopathies
Myopathies
 
Transverse myelitis
Transverse myelitisTransverse myelitis
Transverse myelitis
 
Chorea
Chorea Chorea
Chorea
 
DUCHENNE MUSCULAR DYSTROPHY
DUCHENNE MUSCULAR DYSTROPHYDUCHENNE MUSCULAR DYSTROPHY
DUCHENNE MUSCULAR DYSTROPHY
 
Cerebellar ataxia
Cerebellar ataxiaCerebellar ataxia
Cerebellar ataxia
 
Ataxia
AtaxiaAtaxia
Ataxia
 
Charcot-Marie-Tooth disease
Charcot-Marie-Tooth diseaseCharcot-Marie-Tooth disease
Charcot-Marie-Tooth disease
 
Hereditary neuropathies
Hereditary neuropathiesHereditary neuropathies
Hereditary neuropathies
 
Transverse myelitis
Transverse myelitisTransverse myelitis
Transverse myelitis
 

Semelhante a Spinal muscular atrophy (sma)

A Review on Spinal Muscular Atrophy Clinical Classification, Etiology, Diagno...
A Review on Spinal Muscular Atrophy Clinical Classification, Etiology, Diagno...A Review on Spinal Muscular Atrophy Clinical Classification, Etiology, Diagno...
A Review on Spinal Muscular Atrophy Clinical Classification, Etiology, Diagno...ijtsrd
 
spinal muscular atrophy sma by allelieh
spinal muscular atrophy sma by alleliehspinal muscular atrophy sma by allelieh
spinal muscular atrophy sma by alleliehalengleng28
 
Clinically Isolated syndrome.pptx
Clinically Isolated syndrome.pptxClinically Isolated syndrome.pptx
Clinically Isolated syndrome.pptxMohamed AbdElhady
 
Alzheimer Disease New.ppt
Alzheimer Disease New.pptAlzheimer Disease New.ppt
Alzheimer Disease New.pptSamerHeraki
 
Withdrawal of anti epileptic drugs
Withdrawal of anti epileptic drugsWithdrawal of anti epileptic drugs
Withdrawal of anti epileptic drugsPramod Krishnan
 
Anti epileptic drug withdrawal in adult onset symptomatic epilepsy
Anti epileptic drug withdrawal in adult onset symptomatic epilepsyAnti epileptic drug withdrawal in adult onset symptomatic epilepsy
Anti epileptic drug withdrawal in adult onset symptomatic epilepsyPramod Krishnan
 
Neuroinflammatory msnmonmda resident lecture2020canonico
Neuroinflammatory msnmonmda resident lecture2020canonicoNeuroinflammatory msnmonmda resident lecture2020canonico
Neuroinflammatory msnmonmda resident lecture2020canonicoMonique Canonico
 
Monitoring the Multiple Sclerosis patient
Monitoring the Multiple Sclerosis patientMonitoring the Multiple Sclerosis patient
Monitoring the Multiple Sclerosis patientPramod Krishnan
 
Trainees workshops
Trainees workshopsTrainees workshops
Trainees workshopsYasir Hameed
 
Guia Familias Com Amiotrofia Espinhal!
Guia Familias Com Amiotrofia Espinhal!Guia Familias Com Amiotrofia Espinhal!
Guia Familias Com Amiotrofia Espinhal!Fatima Braga
 
July 6 Webinar: (How) Will Canadians Access Once-in-a- Lifetime Gene Therapy?
July 6 Webinar: (How) Will Canadians Access Once-in-a- Lifetime Gene Therapy?July 6 Webinar: (How) Will Canadians Access Once-in-a- Lifetime Gene Therapy?
July 6 Webinar: (How) Will Canadians Access Once-in-a- Lifetime Gene Therapy?Canadian Organization for Rare Disorders
 
paraneopasticneurologicaldisorder-190123162155.pdf
paraneopasticneurologicaldisorder-190123162155.pdfparaneopasticneurologicaldisorder-190123162155.pdf
paraneopasticneurologicaldisorder-190123162155.pdfMahimaChuohan
 
Paraneopastic Neurological Disorder
Paraneopastic Neurological DisorderParaneopastic Neurological Disorder
Paraneopastic Neurological DisorderAhmad Shahir
 
SMA spinal muscular disease
SMA spinal muscular diseaseSMA spinal muscular disease
SMA spinal muscular diseasejessie9898
 
Whats-New-in-Myasthenia-Gravis.pptx
Whats-New-in-Myasthenia-Gravis.pptxWhats-New-in-Myasthenia-Gravis.pptx
Whats-New-in-Myasthenia-Gravis.pptxIdenyiDanielEwaEde
 

Semelhante a Spinal muscular atrophy (sma) (20)

Spinal muscular atrophy
Spinal muscular atrophySpinal muscular atrophy
Spinal muscular atrophy
 
SMA.pdf
SMA.pdfSMA.pdf
SMA.pdf
 
A Review on Spinal Muscular Atrophy Clinical Classification, Etiology, Diagno...
A Review on Spinal Muscular Atrophy Clinical Classification, Etiology, Diagno...A Review on Spinal Muscular Atrophy Clinical Classification, Etiology, Diagno...
A Review on Spinal Muscular Atrophy Clinical Classification, Etiology, Diagno...
 
Allelieh sma
Allelieh smaAllelieh sma
Allelieh sma
 
spinal muscular atrophy sma by allelieh
spinal muscular atrophy sma by alleliehspinal muscular atrophy sma by allelieh
spinal muscular atrophy sma by allelieh
 
Clinically Isolated syndrome.pptx
Clinically Isolated syndrome.pptxClinically Isolated syndrome.pptx
Clinically Isolated syndrome.pptx
 
Alzheimer Disease New.ppt
Alzheimer Disease New.pptAlzheimer Disease New.ppt
Alzheimer Disease New.ppt
 
Withdrawal of anti epileptic drugs
Withdrawal of anti epileptic drugsWithdrawal of anti epileptic drugs
Withdrawal of anti epileptic drugs
 
International Journal of Neurological Disorders
International Journal of Neurological DisordersInternational Journal of Neurological Disorders
International Journal of Neurological Disorders
 
Anti epileptic drug withdrawal in adult onset symptomatic epilepsy
Anti epileptic drug withdrawal in adult onset symptomatic epilepsyAnti epileptic drug withdrawal in adult onset symptomatic epilepsy
Anti epileptic drug withdrawal in adult onset symptomatic epilepsy
 
Neuroinflammatory msnmonmda resident lecture2020canonico
Neuroinflammatory msnmonmda resident lecture2020canonicoNeuroinflammatory msnmonmda resident lecture2020canonico
Neuroinflammatory msnmonmda resident lecture2020canonico
 
Monitoring the Multiple Sclerosis patient
Monitoring the Multiple Sclerosis patientMonitoring the Multiple Sclerosis patient
Monitoring the Multiple Sclerosis patient
 
Trainees workshops
Trainees workshopsTrainees workshops
Trainees workshops
 
Guia Familias Com Amiotrofia Espinhal!
Guia Familias Com Amiotrofia Espinhal!Guia Familias Com Amiotrofia Espinhal!
Guia Familias Com Amiotrofia Espinhal!
 
July 6 Webinar: (How) Will Canadians Access Once-in-a- Lifetime Gene Therapy?
July 6 Webinar: (How) Will Canadians Access Once-in-a- Lifetime Gene Therapy?July 6 Webinar: (How) Will Canadians Access Once-in-a- Lifetime Gene Therapy?
July 6 Webinar: (How) Will Canadians Access Once-in-a- Lifetime Gene Therapy?
 
paraneopasticneurologicaldisorder-190123162155.pdf
paraneopasticneurologicaldisorder-190123162155.pdfparaneopasticneurologicaldisorder-190123162155.pdf
paraneopasticneurologicaldisorder-190123162155.pdf
 
Paraneopastic Neurological Disorder
Paraneopastic Neurological DisorderParaneopastic Neurological Disorder
Paraneopastic Neurological Disorder
 
Nmosd & mog
Nmosd & mogNmosd & mog
Nmosd & mog
 
SMA spinal muscular disease
SMA spinal muscular diseaseSMA spinal muscular disease
SMA spinal muscular disease
 
Whats-New-in-Myasthenia-Gravis.pptx
Whats-New-in-Myasthenia-Gravis.pptxWhats-New-in-Myasthenia-Gravis.pptx
Whats-New-in-Myasthenia-Gravis.pptx
 

Mais de Azad Haleem

Pediatric Pharmacology:Pharmacokinetics and pharmacodynamics .pptx
Pediatric  Pharmacology:Pharmacokinetics and pharmacodynamics  .pptxPediatric  Pharmacology:Pharmacokinetics and pharmacodynamics  .pptx
Pediatric Pharmacology:Pharmacokinetics and pharmacodynamics .pptxAzad Haleem
 
Neonatal Hypoglycemia approach and Management .pptx
Neonatal Hypoglycemia approach and Management .pptxNeonatal Hypoglycemia approach and Management .pptx
Neonatal Hypoglycemia approach and Management .pptxAzad Haleem
 
Preterm infants Nutrition .pptx
Preterm infants Nutrition .pptxPreterm infants Nutrition .pptx
Preterm infants Nutrition .pptxAzad Haleem
 
Preterm : ABCDE; approach to nutritional assessment in preterm infants.pptx
Preterm : ABCDE; approach to nutritional assessment in preterm infants.pptxPreterm : ABCDE; approach to nutritional assessment in preterm infants.pptx
Preterm : ABCDE; approach to nutritional assessment in preterm infants.pptxAzad Haleem
 
Breastfeeding VS formula feeding .pptx
 Breastfeeding VS formula feeding .pptx Breastfeeding VS formula feeding .pptx
Breastfeeding VS formula feeding .pptxAzad Haleem
 
Role of Supplements in Growth Failure in Children .pptx
Role of Supplements in Growth Failure in Children .pptxRole of Supplements in Growth Failure in Children .pptx
Role of Supplements in Growth Failure in Children .pptxAzad Haleem
 
Degludec Insulin therapy in children
Degludec Insulin therapy in childrenDegludec Insulin therapy in children
Degludec Insulin therapy in childrenAzad Haleem
 
Viral hemorrhagic fevers.pptx
Viral hemorrhagic fevers.pptxViral hemorrhagic fevers.pptx
Viral hemorrhagic fevers.pptxAzad Haleem
 
Micronutrient deficiencies in children .pptx
 Micronutrient deficiencies in children  .pptx Micronutrient deficiencies in children  .pptx
Micronutrient deficiencies in children .pptxAzad Haleem
 
Insulin therapy in children.pptx
Insulin therapy in children.pptxInsulin therapy in children.pptx
Insulin therapy in children.pptxAzad Haleem
 
Diagnostic test for testicular and ovarian disorders in children 2.pptx
Diagnostic test for testicular and ovarian disorders in children 2.pptxDiagnostic test for testicular and ovarian disorders in children 2.pptx
Diagnostic test for testicular and ovarian disorders in children 2.pptxAzad Haleem
 
Diagnostic test for Adrenal disorders in children 2.pptx
Diagnostic test for Adrenal disorders in children 2.pptxDiagnostic test for Adrenal disorders in children 2.pptx
Diagnostic test for Adrenal disorders in children 2.pptxAzad Haleem
 
Diagnostic test for Thyriod disorders in children.pptx
Diagnostic test for Thyriod disorders in children.pptxDiagnostic test for Thyriod disorders in children.pptx
Diagnostic test for Thyriod disorders in children.pptxAzad Haleem
 
Achondroplasia in children.pptx
Achondroplasia in children.pptxAchondroplasia in children.pptx
Achondroplasia in children.pptxAzad Haleem
 
Respiratory Syncytial Virus in children
Respiratory Syncytial Virus in childrenRespiratory Syncytial Virus in children
Respiratory Syncytial Virus in childrenAzad Haleem
 
Growth failure in Children.pptx
Growth failure in Children.pptxGrowth failure in Children.pptx
Growth failure in Children.pptxAzad Haleem
 
Adenoid Enlargement in children.pptx
Adenoid Enlargement in children.pptxAdenoid Enlargement in children.pptx
Adenoid Enlargement in children.pptxAzad Haleem
 
Postbiotics in children
 Postbiotics in children Postbiotics in children
Postbiotics in childrenAzad Haleem
 
Bronchial Asthma in children .pptx
Bronchial Asthma in children .pptxBronchial Asthma in children .pptx
Bronchial Asthma in children .pptxAzad Haleem
 
Fever in Children .pptx
Fever in Children .pptxFever in Children .pptx
Fever in Children .pptxAzad Haleem
 

Mais de Azad Haleem (20)

Pediatric Pharmacology:Pharmacokinetics and pharmacodynamics .pptx
Pediatric  Pharmacology:Pharmacokinetics and pharmacodynamics  .pptxPediatric  Pharmacology:Pharmacokinetics and pharmacodynamics  .pptx
Pediatric Pharmacology:Pharmacokinetics and pharmacodynamics .pptx
 
Neonatal Hypoglycemia approach and Management .pptx
Neonatal Hypoglycemia approach and Management .pptxNeonatal Hypoglycemia approach and Management .pptx
Neonatal Hypoglycemia approach and Management .pptx
 
Preterm infants Nutrition .pptx
Preterm infants Nutrition .pptxPreterm infants Nutrition .pptx
Preterm infants Nutrition .pptx
 
Preterm : ABCDE; approach to nutritional assessment in preterm infants.pptx
Preterm : ABCDE; approach to nutritional assessment in preterm infants.pptxPreterm : ABCDE; approach to nutritional assessment in preterm infants.pptx
Preterm : ABCDE; approach to nutritional assessment in preterm infants.pptx
 
Breastfeeding VS formula feeding .pptx
 Breastfeeding VS formula feeding .pptx Breastfeeding VS formula feeding .pptx
Breastfeeding VS formula feeding .pptx
 
Role of Supplements in Growth Failure in Children .pptx
Role of Supplements in Growth Failure in Children .pptxRole of Supplements in Growth Failure in Children .pptx
Role of Supplements in Growth Failure in Children .pptx
 
Degludec Insulin therapy in children
Degludec Insulin therapy in childrenDegludec Insulin therapy in children
Degludec Insulin therapy in children
 
Viral hemorrhagic fevers.pptx
Viral hemorrhagic fevers.pptxViral hemorrhagic fevers.pptx
Viral hemorrhagic fevers.pptx
 
Micronutrient deficiencies in children .pptx
 Micronutrient deficiencies in children  .pptx Micronutrient deficiencies in children  .pptx
Micronutrient deficiencies in children .pptx
 
Insulin therapy in children.pptx
Insulin therapy in children.pptxInsulin therapy in children.pptx
Insulin therapy in children.pptx
 
Diagnostic test for testicular and ovarian disorders in children 2.pptx
Diagnostic test for testicular and ovarian disorders in children 2.pptxDiagnostic test for testicular and ovarian disorders in children 2.pptx
Diagnostic test for testicular and ovarian disorders in children 2.pptx
 
Diagnostic test for Adrenal disorders in children 2.pptx
Diagnostic test for Adrenal disorders in children 2.pptxDiagnostic test for Adrenal disorders in children 2.pptx
Diagnostic test for Adrenal disorders in children 2.pptx
 
Diagnostic test for Thyriod disorders in children.pptx
Diagnostic test for Thyriod disorders in children.pptxDiagnostic test for Thyriod disorders in children.pptx
Diagnostic test for Thyriod disorders in children.pptx
 
Achondroplasia in children.pptx
Achondroplasia in children.pptxAchondroplasia in children.pptx
Achondroplasia in children.pptx
 
Respiratory Syncytial Virus in children
Respiratory Syncytial Virus in childrenRespiratory Syncytial Virus in children
Respiratory Syncytial Virus in children
 
Growth failure in Children.pptx
Growth failure in Children.pptxGrowth failure in Children.pptx
Growth failure in Children.pptx
 
Adenoid Enlargement in children.pptx
Adenoid Enlargement in children.pptxAdenoid Enlargement in children.pptx
Adenoid Enlargement in children.pptx
 
Postbiotics in children
 Postbiotics in children Postbiotics in children
Postbiotics in children
 
Bronchial Asthma in children .pptx
Bronchial Asthma in children .pptxBronchial Asthma in children .pptx
Bronchial Asthma in children .pptx
 
Fever in Children .pptx
Fever in Children .pptxFever in Children .pptx
Fever in Children .pptx
 

Último

3.21.24 The Origins of Black Power.pptx
3.21.24  The Origins of Black Power.pptx3.21.24  The Origins of Black Power.pptx
3.21.24 The Origins of Black Power.pptxmary850239
 
How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17Celine George
 
5 charts on South Africa as a source country for international student recrui...
5 charts on South Africa as a source country for international student recrui...5 charts on South Africa as a source country for international student recrui...
5 charts on South Africa as a source country for international student recrui...CaraSkikne1
 
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdfP4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdfYu Kanazawa / Osaka University
 
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptxPractical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptxKatherine Villaluna
 
The Singapore Teaching Practice document
The Singapore Teaching Practice documentThe Singapore Teaching Practice document
The Singapore Teaching Practice documentXsasf Sfdfasd
 
In - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptxIn - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptxAditiChauhan701637
 
Prescribed medication order and communication skills.pptx
Prescribed medication order and communication skills.pptxPrescribed medication order and communication skills.pptx
Prescribed medication order and communication skills.pptxraviapr7
 
Philosophy of Education and Educational Philosophy
Philosophy of Education  and Educational PhilosophyPhilosophy of Education  and Educational Philosophy
Philosophy of Education and Educational PhilosophyShuvankar Madhu
 
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...Nguyen Thanh Tu Collection
 
How to Add Existing Field in One2Many Tree View in Odoo 17
How to Add Existing Field in One2Many Tree View in Odoo 17How to Add Existing Field in One2Many Tree View in Odoo 17
How to Add Existing Field in One2Many Tree View in Odoo 17Celine George
 
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRADUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRATanmoy Mishra
 
How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17Celine George
 
CAULIFLOWER BREEDING 1 Parmar pptx
CAULIFLOWER BREEDING 1 Parmar pptxCAULIFLOWER BREEDING 1 Parmar pptx
CAULIFLOWER BREEDING 1 Parmar pptxSaurabhParmar42
 
Human-AI Co-Creation of Worked Examples for Programming Classes
Human-AI Co-Creation of Worked Examples for Programming ClassesHuman-AI Co-Creation of Worked Examples for Programming Classes
Human-AI Co-Creation of Worked Examples for Programming ClassesMohammad Hassany
 
Drug Information Services- DIC and Sources.
Drug Information Services- DIC and Sources.Drug Information Services- DIC and Sources.
Drug Information Services- DIC and Sources.raviapr7
 
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdfMaximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdfTechSoup
 
The basics of sentences session 10pptx.pptx
The basics of sentences session 10pptx.pptxThe basics of sentences session 10pptx.pptx
The basics of sentences session 10pptx.pptxheathfieldcps1
 
How to Manage Cross-Selling in Odoo 17 Sales
How to Manage Cross-Selling in Odoo 17 SalesHow to Manage Cross-Selling in Odoo 17 Sales
How to Manage Cross-Selling in Odoo 17 SalesCeline George
 

Último (20)

3.21.24 The Origins of Black Power.pptx
3.21.24  The Origins of Black Power.pptx3.21.24  The Origins of Black Power.pptx
3.21.24 The Origins of Black Power.pptx
 
How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17
 
5 charts on South Africa as a source country for international student recrui...
5 charts on South Africa as a source country for international student recrui...5 charts on South Africa as a source country for international student recrui...
5 charts on South Africa as a source country for international student recrui...
 
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdfP4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
 
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptxPractical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptx
 
The Singapore Teaching Practice document
The Singapore Teaching Practice documentThe Singapore Teaching Practice document
The Singapore Teaching Practice document
 
In - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptxIn - Vivo and In - Vitro Correlation.pptx
In - Vivo and In - Vitro Correlation.pptx
 
Prescribed medication order and communication skills.pptx
Prescribed medication order and communication skills.pptxPrescribed medication order and communication skills.pptx
Prescribed medication order and communication skills.pptx
 
Philosophy of Education and Educational Philosophy
Philosophy of Education  and Educational PhilosophyPhilosophy of Education  and Educational Philosophy
Philosophy of Education and Educational Philosophy
 
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
 
Finals of Kant get Marx 2.0 : a general politics quiz
Finals of Kant get Marx 2.0 : a general politics quizFinals of Kant get Marx 2.0 : a general politics quiz
Finals of Kant get Marx 2.0 : a general politics quiz
 
How to Add Existing Field in One2Many Tree View in Odoo 17
How to Add Existing Field in One2Many Tree View in Odoo 17How to Add Existing Field in One2Many Tree View in Odoo 17
How to Add Existing Field in One2Many Tree View in Odoo 17
 
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRADUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
 
How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17
 
CAULIFLOWER BREEDING 1 Parmar pptx
CAULIFLOWER BREEDING 1 Parmar pptxCAULIFLOWER BREEDING 1 Parmar pptx
CAULIFLOWER BREEDING 1 Parmar pptx
 
Human-AI Co-Creation of Worked Examples for Programming Classes
Human-AI Co-Creation of Worked Examples for Programming ClassesHuman-AI Co-Creation of Worked Examples for Programming Classes
Human-AI Co-Creation of Worked Examples for Programming Classes
 
Drug Information Services- DIC and Sources.
Drug Information Services- DIC and Sources.Drug Information Services- DIC and Sources.
Drug Information Services- DIC and Sources.
 
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdfMaximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
Maximizing Impact_ Nonprofit Website Planning, Budgeting, and Design.pdf
 
The basics of sentences session 10pptx.pptx
The basics of sentences session 10pptx.pptxThe basics of sentences session 10pptx.pptx
The basics of sentences session 10pptx.pptx
 
How to Manage Cross-Selling in Odoo 17 Sales
How to Manage Cross-Selling in Odoo 17 SalesHow to Manage Cross-Selling in Odoo 17 Sales
How to Manage Cross-Selling in Odoo 17 Sales
 

Spinal muscular atrophy (sma)

  • 2. DEFINITION • Neuromuscular disorders that present in the newborn period with hypotonia and weakness can be caused by a variety of conditions that affect the central nervous system (brain or spinal cord), peripheral nervous system, or skeletal muscle. • Spinal muscular atrophy (SMA) is characterized by degeneration of the anterior horn cells in the spinal cord and motor nuclei in the lower brainstem, which results in progressive muscle weakness and atrophy.
  • 3. GENETICS • The inheritance pattern of chromosome 5q- related SMA is autosomal recessive. • The most common mutation of SMN1 is a deletion of exon 7. • The differences in SMN protein activity and phenotypic expression appear to be related in part to a modifying gene, called survival motor neuron (SMN).
  • 5. EPIDEMIOLOGY • The incidence of spinal muscular atrophy ranges from 4 to 10 per 100,000 live births, • the carrier frequency of disease-causing SMN1 mutations ranges from 1:47 to 1:90. • SMA is the most common monogenic cause of infant mortality.
  • 6. Carrier rate • Approximately 1 in 54 people are carriers1 Birth rate 1. Kolb SJ & Kissel JT. Neurol Clin 2015;33:831–846; 2. About SMA: Overview. Available at: http://smafoundation.org/about-sma/, accessed March 2021 3. Verhaart I et al. J Neurol 2017;264:1465–1473; 4. Farrar MA et al. Ann Neurol 2017;81:355–368; 5. Verhaart I et al. Orphan J Rare Dis 2017;12:124. SMA is a rare disease Worldwide ~1 in 11,000 live births1,4 USA ~1 in 6000–10,000 live births2 Europe ~1 in 3900–16,000 live births3 There may be variation in the birth rate between countries because there is a difference in the incidence of SMA between ethnicities5
  • 7. Classification • These diseases are classified as types 0 through 4, depending upon the age of onset and clinical course. • SMA type 0 (prenatal onset) and SMA type 1 (infantile onset) are the most common and severe types. • SMA type 2 and SMA type 3 have a later onset and a less severe course. • SMA type 4 (adult onset) is the least severe type.
  • 8. CLINICAL FEATURES • The diagnosis of SMA should be suspected for any infant with unexplained weakness or hypotonia. • Weakness is usually symmetrical and more proximal than distal; generally, it is greater in the legs than in the arms • Additional clues suggesting the diagnosis in infants, children, or adults include a history of motor difficulties, Impaired head control, Weak cry and cough, progressive respiratory insufficiency, Swallowing and feeding difficulty, sleep disturbances, hyporeflexia or areflexia, tongue fasciculations, and signs of lower motor neuron disease on examination. • Sensitivity & and intellect are not affected.
  • 9. Clinical classification of SMA • Onset: 10–30 years • Walk independently – Ability may be affected later in life • Normal life expectancy Type 0 Type 1 Type 2 Type 3 Type 4 • Onset: Prenatal • Short life expectancy (usually <1 month) • Onset: 0–6 months • Never sit1 • Short life expectancy (<2 years) • Onset: <18 months • Sit independently • Never walk • Survival into adulthood (prognosis dependent on respiratory involvement) • Onset: >18 months • Walk independently1 – Need assistance – Lose the ability over time • Normal life expectancy Early onset Late onset
  • 11. DIAGNOSIS • Clinical : The diagnosis of SMA should be suspected for any infant with unexplained weakness or hypotonia . • Molecular genetic testing with targeted mutation analysis can confirm the diagnosis of SMA by detection of homozygous deletions of exons 7 of SMN1. • Electromyography in SMA shows abnormal spontaneous activity with fibrillations and positive sharp waves. • Muscle biopsy reveals large groups of circular atrophic type 1 and 2 muscle fibers interspersed among fascicles of hypertrophied type 1 fibers. • SMA was added to the Recommended Uniform Screening Panel (RUSP) for newborns in the United States in 2018, and several states have begun newborn screening for SMA.
  • 12. Early diagnosis of SMA is essential for best patient outcomes • Timely diagnosis is important in all types of SMA, as the success of treatments or medical interventions may depend on identifying individuals as early as possible to begin treatment before irreversible neuronal loss1 – For example, in infants with Type 1 SMA, loss of motor neurons occurs rapidly, within months of life1 – Type 1 SMA accounts for about 50% of individuals diagnosed with SMA 0–3 months Rapid loss of motor units 0–6 months Severe denervation >95% motor unit loss Type 1 SMA2 Early diagnosis of SMA is critical
  • 13. Management • Conservative treatment. • Pharmacological treatment
  • 14. Occupational therapist Orthopaedic consultant Physiotherapist Physician Psychologist Acute care clinicians Consultant neurologist Gastroenterologist Neuromuscular care specialist Nutritionist Pulmonologist Speech-language pathologist The MDT can consist of: Conservative treatment • A multidisciplinary approach is key for the management of individuals with SMA • In SMA, it is important to monitor the various aspects that are known to be involved in disease progression and, when possible, provide anticipatory care.
  • 15. • Nusinersen • Onasemnogene abeparvovec. • Risdiplam. Pharmacological treatment
  • 16. • Since the 2000s, various therapeutics have been developed that aim to restore the physiological levels of SMN proteins. This can be achieved in different ways: FUNCTIONAL SMN PROTEIN LEVELS CAN BE RESTORED IN DIFFERENT WAYS SMN, survival motor neuron. 1. Rao VK et al. J Manag Care Spec Pharm 2018;24:S3–S16; 2. Poirier A et al. Pharmacol Res Perspect 2018;6:e00447. 3.Butchbach MER. Front Mol Biosci 2016;3:7; 4. D'Amico A et al. Orphanet J Rare Dis 2011;6:71. Gene therapy can beused to delivera functionalcopy ofhuman SMNgene to the patient’s own cellstoreplace the missingor defective SMN1gene1 SMN2 expression from SMN2gene transcriptscan be increasedif the inclusionofexon 7is promoted, thereby producing full-length,functional SMN2 protein2 Graphics createdwithBioRENDERsoftware Viruscontaining thecorrectSMN copy SMN1 gene replacement therapy SMN2 gene transcript manipulation 2- 4
  • 17. Drugs used for SMA Nusinersen Administered via lumbar puncture Does not cross the blood–brain barrier The estimated cost of lifetime nusinersen treatment is USD 6.3 million (2019) Trained medical staff and hospital facilities are required for administration Onasemnogene abeparvovec-xioi Limited indication in the US and Japan for use in infants aged <2 years only The initial cost of treatment is USD 2.1 million for a single dose IV administration is unsuitable for older, heavier patients Co-medication with steroids may be required for up to ⁓3 months Limited indication in Europe for use in individuals with Type 1 SMA, or affected individuals with ≤3 copies of the SMN2 gene
  • 18. 3’ss, 3’ splicing site; 5’ss, 5’ splice site; ESE, exonic splicing enhancer; snRNP, small nuclear RNA; SMA, spinal muscular atrophy; SMN, survival of motor neuron. Sivaramakrishnan M, et al. Nat Commun. 2017; 8:1476. MECHANISM OF ACTION • Risdiplam binds two sites in SMN2 pre-mRNA – 5'ss of intron 7 – ESE2 in exon 7 • Binding to the 5’ ss of intron 7 improves recognition by U1 snRNP • U1 snRNP promotes inclusion of exon 7 • The unique specificity of binding two sites increases levels of full-length SMN mRNA and protein while reducing the impact on splicing of other pre-mRNA Maturefull-lengthSMN2mRNA SMN2Pre-mRNA Exon6 Exon8 Exon7 Intron6 Intron7 5’ss ESE2 3’ss 5’ss 3’ss Spliceosome recruitedto initiatethesplicingprocess ISS-N1 Exon6 Exon8 Exon7 Exon7is retainedandamature full-lengthSMN2mRNAis generated Bindingto 5’ssandimprovement of U1/5’ssinteraction risdiplam risdiplam Bindingtothe exonic splicing enhancer to promote Exon 7 inclusion Risdiplam
  • 19. Risdiplam is being investigated The FISH clinical program has enrolled individuals with SMA across a broad spectrum of disease severity (Type 1–3), from newborns to 60-year-old adults, from pre-symptomatic to very weak individuals, both treatment-naïve and previously treated, accounting for the varied needs of the SMA population1–4 *Target enrolment, currently recruiting; †Actual subject number enrolled. 1. ClinicalTrials.gov NCT03779334, accessed March 2021; 2. ClinicalTrials.gov NCT02913482, accessed May 2020; 3. ClinicalTrials.gov NCT02908685, accessed May 2020; 4. ClinicalTrials.gov NCT03032172, accessed March 2021; 5. Baranello G et al. 2019. Presented at the Cure SMA Annual Conference 2019, California, USA. Motor function; 6. Mercuri E et al. Presented at the Cure SMA Annual Conference, 28 June–1 July 2019, Anaheim, CA, USA. FIREFISH2 • Type 1 SMA • 1–7 months old • Dose finding (N=21)5 • Efficacy and safety (N=41†)5 SUNFISH3 • Type 2 or 3 SMA • 2–25 years old • Dose finding (N=51)6 • Efficacy and safety (N=180†)6 JEWELFISH4 • Type 1, 2 or 3 SMA • 6 months–60 years old • Previous SMA treatment • PK/PD and safety (N=174†) RAINBOWFISH1 • Pre-symptomatic SMA • Birth–6 weeks old • Efficacy and safety (N=25*) 6 months 5 years 10 years 20 years 60 years Age at enrolment Birth RAINBOWFISH FIREFISH SUNFISH JEWELFISH
  • 20. FIREFISH is a two-part study that enrolled infants aged 1–7 months with Type 1 SMA1 *A comprehensive list of the primary and secondary endpoints can be found at: https://clinicaltrials.gov/ct2/show/NCT02913482. BSID-III, Bayley Scales of Infant and Toddler Development, Third Edition; CHOP-INTEND, Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders; HINE-2, Hammersmith Infant Neurological Examination, Section 2; PD, pharmacodynamics; PK, pharmacokinetics. 1. ClinicalTrials.gov NCT02913482, accessed March 2021; 2. Servais L et al. Presented at a virtual meeting. 28 April 2020. FIREFISH Type 1 SMA 1–7 months old Rationale1 Assess the safety and efficacy of risdiplam in infants with Type 1 SMA aged 1–7 months Primary endpoints*1 Part 1 Determine the dose for the confirmatory Part 2 Part 2 Proportion of infants who are sitting without support at Month 12 (as assessed by item 22 of the BSID-III Gross Motor Scale) Key secondary endpoints* • Assess the safety, tolerability and PK/PD of risdiplam1 • Evaluate motor function using the BSID-III, the CHOP-INTEND and the HINE-2 at 12 months1 • Assess the time to death or permanent ventilation1 • Evaluate the ability to swallow and feed orally at Month 121,2 • Assess the safety, tolerability and PK/PD of risdiplam1
  • 21. Infants enrolled in FIREFISH with Type 1 SMA from 15 countries1 1. ClinicalTrials.gov NCT02913482, accessed March 2021; 2. Bladen CL et al. J Neurol 2014;261:152–163. • Belgium • Brazil • China • Croatia • France • Italy • Japan • Poland • Russia • Saudi Arabia • Serbia • Spain • Switzerland • Turkey • USA Standards of care may vary between countries and may have an impact on patient outcomes2
  • 22. FIREFISH Part 1 (Cohort B)*:Conclusions at 24 Month1 *High-dose cohort. † Event free in FIREFISH is defined as alive with no permanent ventilation (i.e. no tracheostomy or BiPAP ≥16 hours per day continuously for >3 weeks or continuous intubation >3 weeks, in the absence of, or following the resolution of, an acute reversible event). ‡ As measured by HINE-2. § As measured by CHOP- INTEND. ǁ Safety statements are based on data from all infants in Cohort A and B. Data cut-off: 03 March 2020. BSID-III, Bayley Scales of Infant and Toddler Development, Third Edition; CHOP-INTEND, Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders; HINE-2, Hammersmith Infant Neurological Examination, Module 2; SMA, spinal muscular atrophy. 1. Baranello G et al. FIREFISH Part 1: 24-month safety and exploratory outcomes of risdiplam (RG7916) in infants with Type 1 spinal muscular atrophy (SMA). Presented at the 25th International Annual Congress of the World Muscle Society, 28th Semptember-2nd October 2020
  • 23. Infants continued to achieve motor milestones, such as sitting and standing with support† which would never be seen in natural history studies *Event free in FIREFISH is defined as alive with no permanent ventilation (i.e. no tracheostomy or BiPAP ≥16 hours per day continuously for >3 weeks or continuous intubation >3 weeks, in the absence of, or following the resolution of, an acute reversible event).†As measured by HINE-2. ‡Hospitalizations include hospital admissions ≥1 night. BiPAP, Bilevel Positive Airway Pressure; BSID-III, Bayley Scales of Infant and Toddler Development, third edition; 1. Darras BT, Masson R, Mazurkiewicz-Bełdzińska M, et al. FIREFISH Part 2: 24-month efficacy and safety of risdiplam in infants with Type 1 spinal muscular atrophy (SMA). Presentation at: American Academy of Neurology Annual Meeting; April 17-April 22, 2021; Virtual. 83% (34/41) of infants were event free* at Month 24 of infants were alive and 93% (38/41) 61% (25/41) All patients treated with Risdiplam who were able to sit without support for 5 seconds at Month 12 maintained this ability at Month 24 of infants were sitting without support for at least 5 seconds at Month 24, as measured by the BSID-III No drug-related safety findings led to withdrawal in FIREFISH Part 2 34% (14/41) of all infants did not require hospitalization‡ during 24 months of treatment of infants alive were able to swallow after 24 months of treatment 95% (36/38) FIREFISH Part 2: 24-months Data
  • 24. SUNFISH is a two-part study which enrolled individuals with Type 2/3 SMA, aged 2–25 years SUNFISH Type 2/3 SMA 2–25 years old Rationale Evaluate the safety and efficacy of risdiplam in individuals with Type 2/3 SMA aged 2–25 years, which is representative of the diverse real-world patient population Primary endpoints* Part 1 Determine the dose for the confirmatory Part 2 Part 2 Evaluate motor function using the MFM-32 at 12 months Key secondary endpoints* Assess the safety, tolerability and PK/PD of risdiplam • Evaluate the proportion of participants achieving stabilization or improvement in motor function as assessed by the MFM at Month 12 • Evaluate motor function using the RULM and the HFMSE at 12 months • Assess independence using the SMAIS at 12 months • Assess the safety, tolerability and PK/PD of risdiplam *A comprehensive list of primary and secondary endpoints can be found at: https://clinicaltrials.gov/ct2/show/ NCT02908685. MFM, Motor Function Measure; PD, pharmacodynamics; PK, pharmacokinetics; RULM, Revised Upper Limb Module. ClinicalTrials.gov NCT02908685, accessed March 2021
  • 25. Key exclusion criteria1 SUNFISH was designed to include a patient population representative of the diversity of real-world individuals living with Type 2/3 SMA1–3 A comprehensive list of inclusion/exclusion criteria can be found at: https://clinicaltrials.gov/ct2/show/study/NCT02908685. SMN, survival of motor neuron. 1. ClinicalTrials.gov NCT02908685, accessed March 2021; 2. Mercuri E et al. Presented at the Cure SMA Annual Conference, 28 June– 1 July 2019, Anaheim, CA, USA; 3. Mercuri E et al. Presented at SMA Europe, 5–7 February 2020, Évry, France. Key inclusion criteria1 Part 1 Part 2 • Previous participation in an SMN2-targeting study or gene therapy study • Planned (within 18 months) or previous (<1 year prior) surgery for scoliosis or hip fixation Part 1 Part 2 • Confirmed genetic diagnosis of 5q-autosomal recessive SMA • Aged 2–25 years with Type 2/3 SMA Type 2, or ambulatory or non-ambulatory Type 3 SMA Type 2 or non-ambulatory Type 3 SMA SUNFISH enrolled individuals with a broad functional and clinical range including those with severe scoliosis or contractures2,3
  • 26. SUNFISH enrolled individuals with Type 2/3 SMA from 15 countries1 • Belgium • Brazil • Canada • China • Croatia • France • Germany • Italy • Japan • Poland • Russia • Serbia • Spain • Turkey • USA Standards of care may vary between countries and may have an impact on patient outcomes2 1. ClinicalTrials.gov NCT02908685, accessed March 2021; 2. Bladen CL et al. J Neurol 2014;261(1):152–163.
  • 27. Summary: SUNFISH Part 11 SUNFISH Part 1 is ongoing globally2 98% of individuals in SUNFISH Part 1 have been treated for at least 12 months. 1 dropout in the first 12 months (not because of any safety reason.) SUNFISH Part 1 helped to determine the dose for Part 2 of the study (primary endpoint for Part 1) 100% survival No deaths or drug-related safety findings leading to treatment withdrawal Exploratory MFM-32 results indicate treatment with risdiplam led to improvement in motor function compared with NatHis-SMA A clinically meaningful increase in the MFM-32 total score was observed in individuals independent of age or functional status at baseline Data cut-off for SUNFISH Part 1: 09 January 2019. MFM, Motor Function Measure. 1. Mercuri E et al. Presented at the Cure SMA Annual Conference, 28 June–1 July 2019, Anaheim, CA, USA; 2. ClinicalTrials.gov NCT02908685, accessed March 2021.
  • 28. Individuals receiving risdiplam gain or maintain motor function Risdiplam is the first SMA treatment to have positive pivotal placebo-controlled data in a broad population of children, adolescents and adults—preserving and potentially enabling motor function independence for individuals with Type 2 SMA and non-ambulant Type 3 SMA MFM-32 and RULM scores showed that risdiplam significantly improved motor function after 12 months versus placebo No treatment-related safety findings have led to treatment withdrawal in SUNFISH Part 2 Risdiplam improved independence in activities of daily living, as assessed using the novel SMAIS measure MFM, Motor Function Measure; RULM, Revised Upper Limb Module; SMAIS, SMA Independence Scale. Mercuri E et al. Presented at SMA Europe, 5–7 February 2020, Évry, France. Summary: SUNFISH Part 2
  • 29. RAINBOWFISH is recruiting presymptomatic infants with genetically diagnosed SMA (birth–6 weeks) RAINBOWFISH1 Presymptomatic Birth–6 weeks old Rationale1 Assess the safety, efficacy, PK and PD of risdiplam in pre-symptomatic infants with genetically diagnosed SMA (birth–6 weeks old) Primary endpoint*1 Proportion of participants with two copies of the SMN2 gene and a baseline CMAP† ≥1.5 mV who are sitting‡ without support at Month 12 Key secondary endpoints*1 • Proportion of participants developing clinically manifested SMA • Time to permanent ventilation and/or death • The achievement of motor milestones defined in the BSID-III and by the HINE-2 • Change from baseline score in the CHOP INTEND • Growth measures • Ability to swallow and amount of solid food intake • Degree of innervation by CMAP • PK effects • Respiratory effects by plethysmography *A comprehensive list of primary and secondary endpoints can be found at: https://clinicaltrials.gov/ct2/show/NCT03779334; †CMAP is the composite electrical activity within the target muscle resulting from synchronous activation of a group of motor neurons within a nerve bundle.3 A low CMAP score indicates severe denervation and high disease severity;4 ‡Sitting is defined as ‘sits without support for 5 seconds’, as assessed by Item 22 of the BSID-III Gross Motor Scale. BSID-III, Bayley Scales of Infant and Toddler Development, Third Edition; CHOP INTEND, Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders; CMAP, compound muscle action potential; HINE-2, Hammersmith Infant Neurological Examination, Section 2; PD, pharmacodynamics; PK, pharmacokinetics; SMN, survival of motor neuron. 1. ClinicalTrials.gov NCT03779334, accessed March 2021; 2. Kolb SJ et al. Ann Clin Trans Neurol 2016;3(2):132–145; 3. . Treat NMD https://treat-nmd.org/wp- content/uploads/2016/08/sma-SMA_M.2.2.002.pdf (accessed March 2021); ; 4. Lewelt AJ et al. Muscle Nerve 2010;42(5):703–708.
  • 30. RAINBOWFISH is recruiting presymptomatic infants with genetically diagnosed SMA (birth–6 weeks)1 RAINBOWFISH1 Presymptomatic Birth–6 weeks old Rationale1 Assess the safety, efficacy, PK and PD of risdiplam in presymptomatic infants with genetically diagnosed SMA (birth–6 weeks old) Primary endpoint*1 Proportion of participants with two copies of the SMN2 gene and a baseline CMAP† ≥1.5 mV who are sitting‡ without support at Month 12 Key secondary endpoints*1 • Proportion of participants developing clinically manifested SMA • Time to permanent ventilation and/or death • The achievement of motor milestones defined in the BSID-III and by the HINE-2 • Change from baseline score in the CHOP INTEND • Growth measures • Ability to swallow and amount of solid food intake • Degree of innervation by CMAP • PK effects • Respiratory effects by plethysmography *A comprehensive list of primary and secondary endpoints can be found at: https://clinicaltrials.gov/ct2/show/NCT03779334; †CMAP is the composite electrical activity within the target muscle resulting from synchronous activation of a group of motor neurons within a nerve bundle.3 A low CMAP score indicates severe denervation and high disease severity;4 ‡Sitting is defined as ‘sits without support for 5 seconds’, as assessed by Item 22 of the BSID-III Gross Motor Scale. BSID-III, Bayley Scales of Infant and Toddler Development, Third Edition; CHOP INTEND, Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders; CMAP, compound muscle action potential; HINE-2, Hammersmith Infant Neurological Examination, Section 2; PD, pharmacodynamics; PK, pharmacokinetics; SMN, survival of motor neuron. 1. ClinicalTrials.gov NCT03779334, accessed March 2021; 2. Kolb SJ et al. Ann Clin Trans Neurol 2016;3(2):132–145; 3. Treat NMD https://treat- nmd.org/wp-content/uploads/2016/08/sma-SMA_M.2.2.002.pdf (accessed March 2021); 4. Lewelt AJ et al. Muscle Nerve 2010;42(5):703–708. • In 2016, a Natural History study was performed which assessed motor function and putative electrophysiological, protein and molecular biomarkers in both affected and unaffected infants aged <6 months2 • This study was useful when designing RAINBOWFISH as it provided several reference values (particularly the cut-off baseline CMAP† value of ≥ 1.5 mV for the primary endpoint)2
  • 33. Risdiplam Dosage 60 mg/80 ml 0.75mg/ml Shelf-life: 64 days after reconstitution; 2years for powder 2 Months 2 Years ≈7 Years/20kg Adult 0.2mg/kg/day 0.25mg/kg/day 5mg/da y 1 bottle/≈60 days 1 bottle/≈20 days 1 bottle/max* 12 days Risdiplam USPI M-LB-00000264
  • 34. Risdiplam is not yet registered in Iraq
  • 35. THANKS FOR YOUR ATTENTION